MRI-guided chemoradiotherapy and immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized approach using MRI guidance for chemoradiotherapy combined with immunotherapy for limited advanced esophageal squamous cell cancer that cannot be surgically removed or has spread only to nearby lymph nodes. It aims to improve treatment effectiveness while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of esophageal squamous cell cancer that is locally advanced and cannot be removed with surgery, or you have refused surgery.
- You must be between 18 and 80 years old and have a good performance status (ECOG 0-2, meaning you are able to carry out daily activities with minimal or no assistance).
- You must be able to undergo MRI scans with contrast dye.
- Your blood counts and organ function must be adequate (e.g., white blood cells, platelets, hemoglobin, liver and kidney function within certain limits).
- Women who can become pregnant must have a negative pregnancy test and use effective contraception during and for a period after treatment.
- You must not have had chemotherapy or radiation to the chest in the past 2 years, or have active autoimmune disease requiring systemic treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests whether giving a higher dose of radiation to the main tumor, guided by MRI scans, can improve treatment for a type of esophageal cancer called squamous cell carcinoma. You would first receive standard chemoradiation followed by surgery.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.